Elicera Therapeutics has been awarded funding from the European Innovation Council (EIC) Accelerator Programme.
The grant is sufficient to fully fund Elicera’s planned clinical phase I/II-study evaluating its CAR T-cell therapy ELC-301 in the treatment of B-cell lymphoma, the company states.
“This grant has major positive implications for the development of our CAR T-cell therapy, ELC-301. We have secured around 40 million SEK in total grants for the ELC-301 programme, which according to our estimations means that the upcoming clinical phase I/II-study is now fully funded,” says Jamal El-Mosleh, CEO of Elicera.
“I am very pleased and proud that Elicera was awarded this important EU grant in the face of fierce competition. It is a strong testament to the ground-breaking innovation of our iTANK-enforced CAR T-cell therapies and strengthens the credibility in our development plan for ELC-301,” says Magnus Essand, CSO of Elicera.
Elicera’s drug candidate, ELC-301, constitutes a fourth generation CAR T-cell therapy that targets the CD20 protein which, like CD19, is expressed on all B-cell lymphoma cells. ELC-301 is armed with Elicera’s iTANK-technology platform to elicit a dual mode-of-action and a broad attack on cancer by also activating the patients’ own killer T-cells against the whole set of relevant antigen targets on tumor cells, not only CD19 or CD20.
Photo of Jamal El-Mosleh, CEO of Elicera